Mavatrep
Alternative Names: JNJ-39439335Latest Information Update: 16 Jul 2016
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Analgesics; Benzimidazoles; Small molecules
- Mechanism of Action TRPV1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Musculoskeletal pain; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Musculoskeletal-pain in South Africa (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Musculoskeletal-pain in United Kingdom (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Pain(In volunteers) in France (PO, Tablet)